Abstract
AbstractThis chapter reviews recent progress in developing vaccine platforms and other techniques to formulate vaccine candidates, especially in actual and potential pandemic emergencies. Innovative medical countermeasure (MCM) designs and manufacturing technologies currently in use to combat COVID-19 are primary examples, along with future approaches. Better understanding of viral structure and self-assembly, intended target proteins, and conserved but vulnerable viral epitopes, as well as immune system reactions to viral infection, is foundational to preparedness for the emergence of novel or variant pathogens and rapid development of new MCMs. The prototype pathogen approach to MCM development promotes advance development of vaccine candidates incorporating critical, innovative safety and immunogenicity features into designs based on a well-informed target product profile.
Publisher
Springer International Publishing
Reference45 articles.
1. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al. Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic. Philos Trans R Soc Lond Ser B Biol Sci. 2004;359(1447):1091–105. https://doi.org/10.1098/rstb.2004.1490.
2. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 2021;54(8):1636–51. https://doi.org/10.1016/j.immuni.2021.07.017.
3. Cassetti MC, Pierson TC, Patterson LJ, Bok K, DeRocco AJ, Deschamps AM, et al. Prototype pathogen approach for vaccine and monoclonal antibody development: a critical component of the NIAID Plan for pandemic preparedness. J Infect Dis. 2022;227:1433. https://doi.org/10.1093/infdis/jiac296.
4. CDC. History of Ebola virus disease (EVD) outbreaks. Atlanta, GA: U.S. Centers for Disease Control and Prevention; 2021. https://www.cdc.gov/vhf/ebola/history/chronology.html. Accessed 17 Oct 2021.
5. CEPI. The urgency of now: turning the tide against epidemic and pandemic infectious diseases. CEPI; 2021.